Two local pharmaceutical companies, pharmaceutical business revenue in 2021 exceeds 20 billion yuan

It is the annual report disclosure season recently, and the financial reports of major local pharmaceutical companies and multinational pharmaceutical companies have been released one after another
.

On the whole, most multinational pharmaceutical companies have achieved growth in performance driven by new drugs, and their revenue in China has basically remained above the baseline of 20 billion yuan

Hengrui: Innovative drugs drive sales growth

According to the third quarterly report of Hengrui Medicine in 2021, in the first nine months of 2021, the company has achieved an operating income of 20.
199 billion yuan, a year-on-year increase of 4.
05%
.

The 2021 semi-annual report shows that Hengrui Medicine's innovative drug sales revenue accounts for about 40% of the overall revenue
.

The report shows that, driven by huge investment in research and development, the company has achieved fruitful research and development results in the first half of the year.

At the same time, Hengrui is also actively deploying internationalization, and has established an overseas R&D team of 136 people in the United States, Europe and other places.
The main members are middle and high-level talents from large pharmaceutical companies such as Roche, Novartis, Pfizer, Merck and so on.
experience in global R&D
.

In the first half of 2021, the company has carried out a total of 23 international clinical trials, including 7 international multi-center Phase III projects, and more than 10 studies are in the preparatory stage.

Fosun Pharma: Driven by innovative R&D

According to the financial report data for the third quarter of 2021, Fosun Pharma achieved a cumulative operating income of 27.
048 billion yuan in the first three quarters, a year-on-year increase of 22.
38%
.

Among them, in the third quarter alone, Fosun Pharma achieved operating income of 10.

Fosun Pharma attaches great importance to innovative research and development.
In the first three quarters of 2021, Fosun Pharma invested a total of 3.
151 billion yuan in research and development, a year-on-year increase of 15.
46%
.

Among them, the company's investment in research and development expenses reached 2.

The report shows that during the reporting period, Fosun Pharma steadily promoted the research and development and commercialization of macromolecular drugs
.

For example, in September 2021, the production line of slulimumab injection (ie recombinant anti-PD-1 humanized monoclonal antibody injection) in Xuhui base passed the GMP on-site inspection, and the drug registration application for the second indication of this product was in In September 2021, it was accepted by the State Food and Drug Administration; trastuzumab for injection was approved with a new 60mg specification, which further enriched the choice of clinical drugs

In addition, in the second half of 2021, Fosun Pharma will continue to promote the development and implementation of innovative products and technologies, and strengthen the commercialization system
.

For example, after its joint venture, Fosun Kite’s Yikaida (Ajilunsai Injection), it has actively explored innovative payment models and has been included in the “Huiminbao” payment scope in Changsha, Suzhou and other cities, increasing the availability of the product; at the same time, the second indication of the product (for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma (r/r iNHL) after second-line or more systemic therapy) will be released in 2021 In August 2008, it was included in the breakthrough therapy drug program by the State Food and Drug Administration

Epilogue

It is not difficult to see that innovative R&D is the driving force behind the growth of major pharmaceutical companies
.

Under the continuous high R&D investment of related pharmaceutical companies, its innovative drugs continue to enter the harvest period, which also drives the growth of related companies' performance

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.

Article link: Pharmaceutical Network https://